Abstract
Increased expression of membrane type 1-matrix metalloproteinase (MT1-MMP/MMP14) is associated with the development of many cancers. MT1-MMP may promote the entry of yes-associated protein1 (YAP1) into the nucleus by regulating the regulation of β1-integrin. The purpose of this study was to investigate the effects of MT1-MMP, β1-integrin and YAP1 on the prognosis of gliomas. The expression of proteins was detected by bioinformatics and immunohistochemistry. The relationship between three proteins and clinicopathological parameters was analyzed by the χ 2 test. Survival analysis was used to investigate the effects of three proteins on prognosis. The results showed that high expressions of MT1-MMP, β1-integrin and YAP1 were found in glioblastoma (GBM) compared with lower-grade glioma (LGG). There was a significantly positive correlation between MT1-MMP and β1-integrin (r = 0.387), MT1-MMP and YAP1 (r = 0.443), β1-integrin and YAP1 (r = 0.348). Survival analysis showed that patients with overexpression of MT1-MMP, β1-integrin and YAP1 had a worse prognosis. YAP1 expression was the independent prognostic factor for progression-free survival (PFS). There was a statistical correlation between the expression of MT1-MMP and YAP1 and isocitrate dehydrogenase 1 (IDHl) mutation. Thus, this study suggested that MT1-MMP, β1-integrin and YAP1, as tumor suppressors, are expected to be promising prognostic biomarkers and therapeutic targets for glioma patients.
Highlights
Glioma is the most common primary intracranial tumor
The results showed that the expressions of MT1-MMP, β1-integrin and yes-associated protein1 (YAP1) in GBM were higher than those in lower-grade gliomas (LGG)
To ensure the reliability of the identification of the MT1-MMP, β1-integrin, and YAP1 genes, we validated these via the Gene Expression Profiling Interactive Analysis (GEPIA) using The Cancer Genome Atlas (TCGA) and GTEx databases
Summary
Glioma is the most common primary intracranial tumor. Glioma is classified into four grades (I to IV) by the World of Health Organization (WHO) [1]. Glioblastoma, which belongs to WHO IV, is the most aggressive glioma. It blurs the boundary between the tumor tissue and the surrounding normal brain, which makes it difficult to treat with all existing treatments, and the median survival time for patients with this kind of tumor is 12–15 months [2]. Different from GBM, WHO II grade and WHO III grade have a better prognosis, with an average survival of 78.1 and 37.6 months, respectively, in terms of treatment [3]. Grades II and III are considered to be lower-grade gliomas (LGG) [4–7]. More and more studies have proved that the molecular typing of glioma plays an irreplaceable role in its development, such as IDH1 [8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
